Newly Published Pharmaceutical & HealthCare Industry Reports by GlobalData18 Jan 2012 • by Natalie Aster
Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018. GlobalData estimates that the global cervical cancer market was worth $1,793.3m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 62.7% during 2006–2010. During 2010–2018, the market is expected to record a CAGR of 3.6%, from $1,793.3m in 2010 to $2,377.3m in 2018.
The overall cervical cancer market consists of the cervical cancer prophylactics market and the cervical cancer therapeutics market. The cervical cancer prophylactics market grew at a CAGR of 61.5% from $234.8m in 2006 to $1,598.7m in 2010. The cervical cancer therapeutics market grew at a CAGR of 4.3% from $157.3m in 2005 to $194.5m in 2010.
The cervical cancer prophylactics market is dominated by two vaccines, Gardasil and Cervarix, which are used as preventive vaccines for certain types of HPV. There is one FIC molecule in the late stage of development, which is expected to increase growth in the prophylactics market due to awareness of cervical cancer vaccination programs. Generic erosion of the only therapeutic option in the existing market will be a barrier for the therapeutics market. As a result, significant unmet need is anticipated to persist in the near future. There are some early stage FIC molecules in the early stages of the pipeline, but these are not expected to have an impact in the forecast period.
Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018.
The current competitive landscape for osteoporosis drugs is strong. The market has several therapeutic options for the treatment of osteoporosis. The top selling osteoporosis therapeutics drugs have comparable efficacy levels and safety profiles, with only marginal differences, which have intensified the competition in the osteoporosis therapeutics market.
Although, these agents do not completely satisfy the patients’ needs, there remains a large percentage of people looking for better treatment options in terms of safety, efficacy and dosage patterns for better compliance. Such patients do not have a choice but to continue with the presently available drugs, which only closely meet their needs. Any drug that could successfully cater to the needs of this patient segment is expected to capture a major revenue share of the osteoporosis therapeutics market.
Price per Report: $3.500,00 (Single User License)
More new market research reports by can be found at More new market research reports by can be found at GlobalData page.
To order the report or ask for sample pages contact firstname.lastname@example.org